Alphamab Oncology (HKSE:09966) EBIT per Share : HK$-0.23 (TTM As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology EBIT per Share?

Alphamab Oncology's EBIT per Share for the six months ended in Jun. 2023 was HK$-0.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.23.

During the past 3 years, the average EBIT per Share Growth Rate was 9.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -43.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Alphamab Oncology's EBIT per Share or its related term are showing as below:

HKSE:09966' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -75.5 Med: -62.8 Max: 9.4
Current: 9.4

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Alphamab Oncology was 9.40% per year. The lowest was -75.50% per year. And the median was -62.80% per year.

HKSE:09966's 3-Year EBIT Growth Rate is ranked better than
58.04% of 1306 companies
in the Biotechnology industry
Industry Median: 3.5 vs HKSE:09966: 9.40

Alphamab Oncology's EBIT for the six months ended in Jun. 2023 was HK$-36.0 Mil.

Alphamab Oncology EBIT per Share Historical Data

The historical data trend for Alphamab Oncology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology EBIT per Share Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.72

-0.53

-0.52

-0.37

-0.23

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial								-0.18	-0.17	-0.21	-0.04	-0.19

Alphamab Oncology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Alphamab Oncology's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-347.875	/	936.502
=	-0.37

Alphamab Oncology's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-35.98	/	957.141
=	-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.23

Alphamab Oncology (HKSE:09966) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Alphamab Oncology EBIT per Share Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines